The FDA approved FINTEPLA for the treatment of rare epilepsy.

1 report, 1 independent Updated Aug 5

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

FDA UCB

Keep exploring

Part of

Brainstorm and Loulou Foundation provided funding for rare genetic epilepsy initiatives and adopted FDA-encouraged methodologies. All 1 developments

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
UCB
biopharmaceutical company headquartered in Brussels, Belgium

Nothing else this week.

Related events

Jazz Pharmaceuticals acquires Actio Biosciences for rare epilepsy portfolio, and the company's investigational drug secures multiple FDA designations.Aug 11

Coverage

Newest first; wire copies grouped

Aug 5prnewswire.com